Novo Nordisk raised its annual profit guidance following a robust first-quarter performance, driven by strong sales of its weight-loss drugs. The Danish pharmaceutical company reported a 32% increase in sales, reaching 96.8 billion Danish kroner ($15.2 billion), significantly surpassing analyst expectations of 71.3 billion kroner. Operating profit surged 65% year-on-year to 59.6 billion kroner, also exceeding forecasts. Notably, the launch of the oral weight-loss drug Wegovy in the U.S. contributed significantly, with sales hitting 2.26 billion kroner, far above the expected 1.16 billion kroner.
This impressive performance highlights the growing impact of GLP-1 drugs in the obesity care market, which saw overall sales rise by 22%. While sales of the injectable Wegovy fell slightly short of expectations, the overall momentum in this sector is clear. Novo’s revised guidance reflects confidence in continued growth, with adjusted sales now expected to contract by -4% to -12% through 2026.
Market professionals should note the potential for increased volatility in Novo’s stock as investor sentiment shifts with the evolving sales trajectory of its GLP-1 products.
Source: cnbc.com